Abstract: Adenosine (ADO) acts as an inhibitory neuromodulator throughout the central and peripheral nervous system and can regulate seizure and nociceptive activity. However, the positive actions of systemically administered ADO are usually accompanied by undesirable side effects such as hypomobility and cardio-suppression. Adenosine kinase (AK) is the primary metabolic enzyme regulating intra-and extracellular concentrations of ADO. We review the recent development of structurally novel nucleoside and nonnucleoside AK inhibitors that demonstrate high specificity for the AK enzyme. Several of these compounds have shown significant beneficial effects in animal models of epilepsy and pain with an improved preclinical therapeutic window over direct acting ADO receptor agonists.
INTRODUCTION
The endogenous purine nucleoside, adenosine (ADO) interacts with specific extracellular G-protein coupled receptors (termed P1 receptors), to serve as an extracellular signaling molecule potentially mediating a variety of therapeutically useful physiological responses. Consequently, the identification of compounds that mimic or potentiate the actions of ADO has been the subject of substantial drug discovery efforts. An approach that has received attention in recent years is the discovery of compounds that augment the concentrations and actions of endogenous ADO by inhibiting the ADO-metabolizing enzyme, ADO kinase (AK, Figure 1 ). This review briefly summarizes the role of ADO as a signaling molecule and discusses the rationale for AK inhibition as an approach to developing novel therapeutic agents. In addition, key compounds are highlighted, and potential therapeutic applications of AK inhibitors to the control of seizure activity and pain are discussed.
While it has long been appreciated that purines can modulate neurotransmission [1] , the complexities associated with the rapid metabolic degradation of ATP to adenosine (ADO) and the plethora of identified purinergic cell surface receptor subtypes has obscured the delineation of mechanistic specificity in the neuromodulatory actions of ATP and ADO [2, 3] . The molecular cloning and characterization of distinct super families for ADO-sensitive (P1) and ATP-sensitive (P2) receptors during the last ten years has provided a means to systematically interrogate purinergic neuromodulation. Since multiple ADO-sensitive P1 receptor subtypes likely contribute to the modulation of neuronal excitability in the CNS [4] , the selective modulation of ADO availability at sites of neuronal hyperexcitability and/or tissue inflammation has also emerged as a potential neuroprotective mechanism [5] . Extracellular ADO functions as an inhibitory brake to limit cellular energy demand and results in a variety of neuroprotective actions including decreased seizure activity, reductions in hypoxic cell death, anti-inflammation and antinociception [6] . Consequently, ADO has been termed a "retaliatory" or "homeostatic" modulator of cellular activity [7] . ADO produces these effects by activating a family of P1 G-protein coupled receptors (A 1 , A 2A , A 2B , A 3 ).
ADO has a half-life on the order of seconds in physiological fluids [8] , and its beneficial actions are, therefore, restricted to the tissue and cellular site where it is released. Reuptake of ADO into the cell, followed by its intracellular metabolism is responsible for the rapid disappearance of ADO from the extracellular space [9] . Since ADO has been shown to effectively limit pathophysiological processes resulting from tissue trauma and injury, the identification of ligands that mimic or potentiate the beneficial actions of ADO has been the subject of substantial drug discovery efforts [10, 11] . Because inhibition of AK can significantly increase level of endogenous ADO, the development of specific AK inhibitors represents a promising strategy for the rational development of clinically useful purinergic drugs. AK (ATP:adenosine 5'-phosphotransferase, EC 2.7.1.20) is a cytosolic enzyme that catalyzes the phosphorylation of ADO to AMP and is one of two enzymes responsible for ADO metabolism. ADO deaminase (ADA, adenosine aminohydrolase, EC 3.5.4.4) also contributes to ADO conversion, but AK appears to predominate under physiologic conditions [9] . The mammalian AK enzyme has been cloned [12, 13] and crystallized [14] and found to contain two ADO binding sites, a catalytic site with high affinity for ADO and a low affinity regulatory site that may be the MgATP 2- binding site [15, 16] . Since the predominant ADO-specific transport system operates as a non-concentrative, bidirectional, facilitated diffusion transporter, ADO transport is largely driven by its concentration gradient across the cell membrane. Thus, AK inhibition has the net effect of decreasing the effectiveness ADO cellular reuptake [17] , thereby potentiating the local concentration of ADO in the extracellular compartment.
Since the actions of endogenous ADO are highly localized, AK blockade may be more effective in cells undergoing accelerated ADO release [18] . In addition, the effects of AK inhibitors should be more pronounced at tissue sites where pathophysiological changes result in ADO release, thereby limiting systemic side effects [19, 20] . The ability of AK inhibitors to augment ADO availability has been demonstrated in hippocampal and spinal cord slices in vitro [21, 22] and in vivo following peripheral inflammation and excitotoxic insults to rat striatum [20, 23] . These data demonstrate that systemically administered AK inhibitors can elicit site and event specific enhancement of endogenous ADO levels in vivo. Furthermore, AK inhibitors can amplify the actions of ADO independent of ADO receptor subtype. This may be a potential advantage in cases where a multiplicity of ADO receptor subtypes is involved in the therapeutic effect, such as in inflammation [24] . Enhancing ADO availability may also have therapeutic utility in decreasing perioperative analgesic and/or anesthetic requirements [25, 26] .
Novel nucleoside and non-nucleoside inhibitors of AK (Figure 2) have recently been reported [27] [28] [29] [30] that show a high degree of selectivity and have in vivo effects consistent with the augmentation of the actions of endogenous ADO in animal models of pain, inflammation and seizure activity [31] [32] [33] . ADO receptor antagonists block these effects, thus providing further support that the underlying mechanism mediating the effects of AK inhibitors in vivo is an increase in endogenous ADO concentrations followed by activation of ADO (P1) receptors
STRUCTURES

AND ACTIVITIES OF AK INHIBITORS
Since an earlier review of the medicinal chemistry of AK inhibitors [5] , several new agents of even greater potency and variety have been disclosed (Figure 3) . Several of these agents have proven to be important research tools enabling the study of ADO-mediated processes, while their efficacy in animal models also suggests that such agents may have potential in treating human pathologies. [33] and are active in a variety of pain models ( Table 2 ) [35, 36] . The potential of 1 and 2 to serve as drugs, and to a lesser extent, their utility as pharmacological tools, is compromised by side effects which include a profound propensity to suppress locomotion in rodents, and to induce hypothermia [17] . The Gensia/Metabasis team has described a number of analogs of 1 and 2, and further developed the SAR to produce a large family of nucleoside-like agents (4 -12) . Experiments demonstrated the efficacy of 5-IT (1) and 5'd-5IT (2) to inhibit MES-induced seizures [29, 30, 33] . A variety of ribonucleoside analogs were created with potent AK inhibition (4-10o), and shown to be efficacious in suppressing MES-induced seizures in rats. The ED 50's for these compounds in the MES assay ranged from 0.7 (10h) to 15.9 (4) mg/kg. The anti-seizure efficacy of 7 (GP-3269) was counteracted by coadminstration with the ADO receptor antagonist theophylline, indicating that the anti-seizure activity was mediated by increased levels of ADO acting at ADO receptors. Additionally, it was also found that the 4'-epimeric analogs 11 (GP-790) and 12 (GP-947), the 'lyxo' configuration of the five-membered ring, retained potent activity in the epilepsy models [37] .
The Abbott team has produced a large number of nucleoside-like analogs, which have been shown to attenuate nociception. Compounds 13 and 14 are carbocyclic nucleosides, distinguished from the 'natural' furanose analogs 1 -12, by having a cyclopentane ring, which renders the analogs impervious to acid or enzyme-catalyzed hydrolysis, and also by a deletion of the 4'-methylene moiety, the so-called 4'-truncation [38, 39] . While a large number of analogs have been produced, the most notable, and best characterized compounds are 13 (A-134974) and 14 (A-286501). Compound 13 is extremely potent to inhibit AK in vitro (IC 50 = 60 pM), and is effective in the carrageenan model of thermal hyperalgesia (ED 50 = 1 µmol/kg) [124] . Compound 14 is somewhat less potent in vitro (IC 50 = 0.47 nM), but of comparable efficacy (ED 50 = 2 µmol/kg) against thermal hyperalgesia [5, 40] .
There are a number of non-nucleoside AK inhibitors that have been disclosed, including the natural product 5-bromopyrrolopyrrolidine, the first compound recognized in this class [17] . The more recently described AK inhibitors generated from the Abbott team were originally found through a high throughput screen and are generally more potent than 5-bromopyrrolopyrrolidine. By optimizing this series, the pyridopyrimidine ABT-702 (15) was produced, a compound with exceptional potency (ED 50 = 0.7 µmol/kg) against thermal hyperalgesia [27, 31] . More recently, described non-nucleoside analogs have been designed with the goal of improving the ADME properties and the extremely low water solubility (pyridopyrimidine series), as well as reducing the propensity to suppress locomotion while retaining or improving the antinociceptive potency of ABT-702 (15) . To this end, the morpholine ring in ABT-702 (15) was replaced with a variety of polar groups, which in 16 resulted in a potent (IC 50 = 8 nM) analog with improved ADME properties (16: 3.6 hr t 1/2 , 46% oral bioavailability in rat; 5.2 hr t 1/2 , >100% oral bioavailability in dog; vs. 15: 0.9 hr t 1/2 , 23% oral bioavailability in the rat; 1.2 hr t 1/2 and 62% oral bioavailability in dog) [41] . Compound 16 was also effective in the carrageenan model of thermal hyperalgesia (ED 50 = 2 µmol/kg, i.p.) and was orally active, though still not as potent as ABT-702 (15) . Among other compounds bearing morpholine replacements, select members retained the analgesic properties of the series as well as a reduced propensity to inhibit rat locomotion. For example, 17, at 4 µmol/kg (i.p.), reduced carrageenan-induced hyperalgesia, but produced little or no motor suppression at 30 and 100 µmol/kg [42] .
The 5-position of the pyridopyrimidine ring in ABT-702 (15) has also been modified, and in the case of the 5-alkylsubstituted compound (18) , the in vitro potency was increased 12-fold over ABT-702 (15, IC 50 = 0.17 nM), but without an increase in the in vivo potency (ED 50 = 3 µmol/kg, i.p.). Solubility was not improved with most of the 5-alkyl analogs, with the exception of the highly soluble 19, which reduced hyperalgesia (ED 50 = 2 µmol/kg, i.p.), but was inactive after oral administration [43] .
A different type of modification, the incorporation of a nitrogen atom at the 5-position of the pyridopyrimidine ring allows retention of activity. Compound 20 retained in vitro potency (IC 50 = 10 nM), as well as in vivo activity (ED 50 = 3 µmol/kg, i.p.) against carrageenan hyperalgesia [44] . The clearest demonstration of the solubility enhancement among 5-aza analogs is seen in 21, which is extremely water soluble (>200 mg/ml), and retains potency both in vitro (IC 50 = 9 nM) and in vivo (ED 50 = 10 µmol/kg, i.p.) [45] . The incorporation of an oxygen at the 5-position of the pyridopyrimidine ring, as in 22, has also allowed for potent AK inhibition in vitro (IC 50 = 4 nM), as well as much higher solubility (10 mg/ml) than ABT-702 (15), but the compound showed no efficacy in pain models.
The incorporation of additional alkyl or aryl groups at the 6 position of the pyridopyrimidine gave compounds, such as 23 (IC 50 = 3 nM) and 24 (IC 50 = 5 nM), a similar potency to the parent, ABT-702 (15) [46] . Both compounds, at 10 µmol/kg, i.p., were effective to reduce formalin-induced nocifensive responses (chemogenic nociception) by 40% . However, as might be expected from the increased lipophilicity imparted by the aromatic rings in 23 and 24, the analogs of the series were poorly soluble, and unfortunately, not improved over ABT-702 (15).
The compounds 25 and 26 represent a unique structural class of AK inhibitors that are distinct from the pyridopyrimidines [47] . Although they are non-nucleosides, and were designed as analogs of 15, the pyrimidine heterocycles 25 and 26 are somewhat structurally reminiscent of the pyrimidine nucleoside analogs described by Lee [48] . Compounds such as 27 (IC 50 = 2 nM) were designed as analogs of the natural product clitocine, 28 (IC 50 = 2 µM). Compounds 25 (IC 50 = 15 nM) and 26 (IC 50 = 2 nM), as well as similar analogs in the series, demonstrated high potency in vitro, and many analogs were also active in a variety of pain models. In addition to the benefits of its non-nucleoside structure, and relatively low molecular weight, compound 26 has a basic amine moiety, a functionality imparting relatively high water solubility.
Although most of the compounds ( 4-28) have been tested in specific animal models of disease (either seizure or pain models), it is likely that the potent compounds would have therapeutic utility across the relevant pathological states like the prototypical compounds, 1-3. To this end, a new structural class of potent AK inhibitors, the furopyrimidines (29, 30) has been disclosed in a patent application by the team from Bayer [49] . Although no activity in pain or epilepsy models was disclosed, it may be anticipated that the compounds of the series will have in vivo activity, based on their high AK potency (29, IC 50 = 10 nM; 30 IC 50 5 = nM), and also that that they share some structural similarity with a number of pyridopyrimidines (15 -22) which reduce rat hyperalgesia.
THERAPEUTIC TARGET: EPILEPSY
Epilepsy is a common neurological disorder affecting approximately 1% of the population. While effective antiseizure medications are available for many types of epilepsy, seizures persist in approximately 35% of patients with partial epilepsy. Therefore, the need for new therapeutic approaches to the treatment of epilepsy has stimulated research on the role of ADO in seizure disorders. Converging lines of evidence strongly support the involvement of ADO in the generation, patterning and maintenance of seizure activity. Specifically, ADO has been shown to be released during seizures, ADO agonists can suppress seizures and raise seizure thresholds, while ADO antagonists are proconvulsant [50] [51] [52] [53] . These effects are not surprising in view of the powerful inhibitory activity of ADO on synaptic activity and neurotransmitter release [54] .
The underlying hypothesis is that increased metabolic demand generated in the central nervous system by seizure activity results in increased intracellular synthesis of ADO from the hydrolysis of nucleotides (ATP, ADP, AMP) by several endo-and ectonucleotidases [54] [55] [56] [57] [58] . ADO levels then increase in the extracellular space via efflux of ADO through a bi-directional transporter, where ADO interacts with cell-surface receptors (i.e., A 1 , A 2A , A 2B and A 3 ) to modulate synaptic activity [59] . The effects of ADO on neural activity are primarily inhibitory [60] , with spontaneous neuronal firing in the cortex, thalamus, hippocampus and cerebellum inhibited by iontophoretic application of ADO [61] . In the hippocampus, inhibition of synaptic activity may be due exclusively to ADO action on A 1 receptors, as a null mutation in the ADO A 1 receptor gene completely abolishes synaptic modulation by ADO [62] . Furthermore, ADO acts both presynaptically and postsynaptically [63] . Presynaptically, ADO inhibits the release of excitatory and inhibitory neurotransmitters, including glutamate, acetylcholine, norepinephrine and GABA. Postsynaptically, ADO hyperpolarizes neurons through an increase in potassium conductance [64] [65] [66] .
Release of Adenosine Following Seizures
A number of studies have reported that seizures can increase extracellular levels of ADO [67] [68] [69] [70] [71] [72] [73] [74] . During and Spencer [72] measured hippocampal levels in humans by microdialysis before, during and after complex partial seizures. They reported a dramatic 6-31 fold increase in extracellular ADO, with levels reaching as high as 65 µM [72] . Because these levels would be expected to activate ADO receptors, the increase in extracellular ADO could contribute to the termination of ongoing seizure activity as well as the postictal refractory period [75, 76] . Using in vivo microdialysis, substantial increases in extracellular levels of ADO have also been found in the hippocampus of rats undergoing pharmacological seizures produced by kainite, bicuculline or pentylenetetrazol [73] Brief seizures produced by bicuculline resulted in modest increases (i.e., 2 fold) in extracellular ADO, while severe and prolonged seizures produced by pentylenetetrazol resulted in 4-5 fold increases. Interestingly, the levels of the ADO metabolites, inosine and hypoxanthine, were also substantially increased in this preparation, indicating rapid metabolism of ADO after release [73] .
Seizure Induced Changes in Adenosine A 1 Receptor Density in Animals and Man
ADO receptor density can be upregulated by chronic blockade by theophylline [77, 78] and receptor up-regulation has been found to increase the thresholds for pharmacologically induced seizures [79, 80] as well as kindled seizures [51] . Additionally, repeated or prolonged increases in extracellular ADO, resulting from seizures, may modify ADO receptors [81] . This possibility has been examined in several animal models of epilepsy and in epileptic patients. In animal models, seizures generally increase the density of A 1 receptors. Seizures induced by pentylenetetrazol (PTZ) up-regulated A 1 receptors in mouse cortex, hippocampus, thalamus and cerebellum, although an earlier study with PTZ had reported [82, 83] decreased A 1 receptor density in cerebellum [84] . Similarly, bicuculline-induced seizures increased A 1 receptor density in substantia nigra, amygdala, hippocampus and septum [85] . Repeated bicuculline seizures in developing rats (i.e., P5-7) also increased A 1 receptor density and G-protein coupling, but did not affect A 2A receptors. However, seizures initiated later in develop-ment (i.e., p15-17) decreased A 2A density and increased receptor affinity [86] , indicating that the effects of seizures may not be exclusively on A 1 receptors. Seizures produced by repeated electroconvulsive shock also increased A 1 receptor density in cortex, but not hippocampus, striatum or cerebellum [87] . More recently, seizures produced by the convulsant drug 3-mercaptopropionic acid were found to increase A 1 receptor density throughout the hippocampus of rats [88] .
In contrast, A 1 receptor density was not altered in the cortex or hippocampus of amygdala-kindled seizures, although receptor affinity was elevated in the hippocampus [89] . Ekonomou and colleagues [90] studied the distribution of A 1 receptor in the brains of genetic absence epilepsy rats. A lower density of A 1 receptors was found in the reticular and anterior thalamic nuclei, as well as basal ganglia of these rats. They suggested that the low level of A 1 receptors could underlie the development of spike and wave discharges characteristic of these genetically epileptic rats.
In humans, Angelatou and colleagues [91] found a 48% increase in A 1 receptor density in temporal neocortex surgically removed to control partial epilepsy. However, Glass and colleagues [92] reported a decrease in A 1 receptors in the temporal lobe of postmortem tissue from patients suffering from complex partial seizures. Reasons for the discrepant findings between these two human studies are not clear, but could be related to differences in the types of control tissue used (i.e., neocortex from tumor patient's vs. postmortem tissue).
Anticonvulsant Effects of Adenosine Agonists
ADO and specific ADO receptor agonists exert potent anticonvulsant effects in a variety of seizure models, including pharmacologically induced [93] [94] [95] and electrically kindled seizures [96] [97] [98] . The anticonvulsant activity associated with ADO receptor activation appears to be primarily mediated via activation of the A 1 receptor subtype [94, 95, [99] [100] [101] [102] . However, systemic administration of the ADO A 2A receptor agonist, 2-chloro-N6-cyclopentyladenosine (CPA) effectively suppressed audiogenic seizures in genetically epilepsy-prone mice [103] Seizures remained suppressed when CPA was injected along with 8-(psulphophenyl)theophylline, a peripherally acting ADO receptor antagonist, indicating that the effects of CPA were due to central nervous system activity on A 2A receptors.
Direct injection of ADO agonists into a seizure focus can also block seizure activity [104] [105] . In a mouse model of pharmacoresistant epilepsy in which recurrent seizures are produced by direct injection of kainate into the hippocampus, systemic injection with 1.5 or 3 mg/kg of the ADO A 1 receptor agonist, 2-chloroadenosine completely suppressed seizure activity for over 3.5 hr [106] . The combination of N6-cyclohexyladenosine, an ADO A 1 agonist, with major antiepileptic drugs (e.g., diazepam, sodium valproate, diphenylhydantoin, phenobarbital, carbamazepine) resulted in enhanced anticonvulsant activity in mice against seizures produced by electroconvulsive shock or pentylenetetrazol [107] . In in vitro experiments, ADO has been shown to reduce seizure activity in the rat hippocampus using the zero magnesium model of epilepsy. Concentrations above approximately 10 mM were effective [108, 109] , and similar effects have been observed in vitro in slices of human epileptogenic cortex [110] . The novel ADO binding enhancer, PD81,723 which increases ADO agonist binding to A 1 receptors was also anticonvulsant in the in vitro lowmagnesium epilepsy model in rat hippocampus [108] . These studies clearly demonstrate that across a variety of animal seizure models and in human tissue, increased ADO activity can be anticonvulsant.
Proconvulsant Effects of Adenosine Antagonists
The methylxanthines, including caffeine and theophylline, increase the severity of established seizures and facilitate the rate of kindling in rats [111] [112] . High levels of caffeine can also induce tremors and seizures in humans [113] . Young and Dragunow [114] reported that systemic injection of 8-cyclopenyl-1,3-dimethylxanthine, an ADO receptor antagonist, could produce recurrent seizures that model status epilepticus in rats. 8-(p-sulphopnenyl)-theophylline, which has a limited ability to cross the bloodbrain-barrier, produced similar status-type seizures only when injected directly into the brain. Consistent with the findings described above that anticonvulsant activity is primarily associated with A 1 receptor agonists, status epilepticus seizures were prevented by systemic administration of an A 1 , but not an A 2A agonist. Status epilepticus can also be modeled by systemically injecting neonatal rats (e.g., postnatal day 12) with a combination of lithium and pilocarpine [115] . In this model, aminophylline, an ADO receptor antagonist, resulted in longer duration seizures, more severe motor and memory deficits, and evidence of cell injury in the hippocampus (i.e., cell loss, moss fiber sprouting) that was not observed without administration of aminophylline [116] .
Adenosine Releasing Cells and Seizures
While ADO and ADO agonists have potent anticonvulsant activity in several animal seizure models, their direct use to treat clinical epilepsy has been limited by the undesirable sedation, hypothermia and hypotension resulting from peripheral blockade of ADO activity [117] . In order to deliver ADO directly to the central nervous system for the treatment of seizure disorders, ADO releasing cells were engineered and injected into the lateral cerebral ventricles of hippocampal kindled rats [118, 119] . Specifically, baby hamster kidney (BHK) cells were mutagenized, and subclones lacking AK activity were selected and encapsulated within PES polymer hollow-fill capsules. Similarly, ADO-releasing fibroblasts from ADO deaminase knockout mice were encapsulated. Both cell types showed substantial release of ADO prior to implantation. Implantation of either encapsulated cell-type significantly reduced behavioral and electrographic kindled seizure activity for more than three weeks after implantation. AK deficient BHK cells were the most effective in releasing ADO and limiting seizure severity. Importantly, the anticonvulsant activity was transiently reversed by treatment animals with DPCPX, a selective ADO A 1 receptor antagonist. However, substantial death of the encapsulated cells was found 24 days after implantation into kindled animals. These novel results are consistent with pharmacological data demonstrating anticonvulsant activity of ADO and ADO agonists. The authors concluded that such an approach could be useful for treatment of pharmacoresistant clinical epilepsy.
Anticonvulsant Properties of Adenosine Kinase Inhibitors (AK)
More recent research has focused on the development of AK inhibitors as anticonvulsant agents. As described above, under basal conditions ADO is primarily metabolized by AK [5, 9, 33, 57] and inhibitors of AK have been shown to increase ADO release from electrically depolarized rat hippocampal slices [57] and from rat spinal cord slices [22] . An additional attractive aspect to the development of AK inhibitors is that they potentiate ADO actions at the site of release, and therefore represent a localized, use dependent strategy for enhancing the anticonvulsant properties of ADO, with the potential of significantly limiting unwanted side effects [5, 33] . In an early study, seizures produced by direct microinjection of bicuculline into the prepiriform cortex of rats were shown to be potently blocked by subsequent injection of the AK inhibitors, 5'-amino-5'-deoxyadenosine or 5-IT, but not by the ADA inhibitor 2'-deoxycoformycin [120] . Gouder et al. [121] provided additional evidence that adenosine kinase can play a critical role in the regulation of seizure activity. They used a model of human mesial temporal lobe epilepsy in which kainic acid injected into the dorsal hippocampus of mice results in spontaneously recurring seizures after a latent period of approximately 2 weeks. Adenosine kinase activity markedly increased in the hippocampus of kainic acid-injected mice prior to the occurrence of spontaneous seizures, and in parallel with the appearance of astrocytes that were intensely immunoreactive for adenosine kinase. Seizures could be completely suppressed for up to 6 hr by injection with 5-iodotubercidin, and this anticonvulsant effect was reversed by the A1-selective antagonist DPCPX. The authors suggest that the increase in AK activity in the hippocampus of epileptic animals could contribute to the development of chronic seizure activity by reducing endogenous adenosine levels.
Subsequent development of a series of substituted tubercidin molecules resulted in the identification of novel AK inhibitors with significant anticonvulsant activity [29, 30] . From this series a potent AK inhibitor, GP-3269, was identified with enhanced oral bioavailability (60%), and relatively long plasma half-life (> 4-hr). This compound inhibited the hind-limb extensor component of electroshock in rats with an IC 50 =11 nM, without producing marked cardiovascular effects [122] .
The anticonvulsant effects of GP-3269 have also been demonstrated in amygdala-kindled rats [123] . Adult, male rats were stereotaxically implanted, unilaterally, with stimulating/recording electrodes into the amygdala, and stimulated daily until fully kindled, Stage 5 seizures were elicited [124] . GP-3269 was then administered orally at 10, 20 or 40 mg/kg. Animals were tested two hours later for behavioral seizure severity (i.e., seizure stage) and electrographic afterdischarge duration. At 20 and 40 mg/kg, GP-3269 significantly reduced both behavioral seizure stage (Figure 4) and electrographic afterdischarge duration ( Figure  5 ) compared to vehicle controls. Oral treatment with 40 mg/kg of carbamazepine reduced seizure stage and afterdischarge to a similar degree. These findings support the role of ADO in modulating neural activity, and suggest that AK inhibitors, such as GP-3269 may be useful anticonvulsants.
In summary, several lines of research now strongly support the conclusion that ADO can limit excessive neuronal activity during episodes associated with periods of high metabolic demand, and thereby function as an endogenous anticonvulsant [50, 51] . While administration of ADO receptor agonists, particularly A 1 agonists, has been shown to be anticonvulsant in many studies, the continued development of adenosinergic compounds for use in epilepsy has been hampered by the lack of highly effective compounds without significant side effects. The recent development of novel therapeutic strategies for ADO, including the development of AK inhibitors, promises to break this impass and finally provide an avenue for new ADO-based anticonvulsant therapies.
THERAPEUTIC TARGET: PAIN
While there is an obvious therapeutic appeal for the use of AK inhibitors to control seizure activity, the interest in this pharmacology is not limited to this disease state. The potential therapeutic utility for the management of pathological pain syndromes has also spurned the development of several novel AK inhibitors ( Table 2) . To this end, prototypical and structurally novel AK inhibitors have been shown effective in various animal models of pain [32, 36, 40, 125, 126] . The development of novel pharmacological analgesics like AK inhibitors, has been greatly aided over the past decade by our increased understanding of the nociceptive system. Importantly, pain is not a unimodal sensory phenomenon, but rather a series of complex neurophysiological responses to acute or persistent injury. Distinctive mechanisms contribute to acute nociceptive states, to pain arising from persistent or chronic tissue damage (inflammatory pain), and to pain arising from injury to the nervous system (neuropathic pain) [127] . Thus, particular neurotransmitter systems may contribute to discrete pain states. Furthermore, the psychophysical parameters used to describe nociceptive processing have been refined to differentiate the behavioral responses evoked by acute noxious stimuli (acute nociception), from those evoked following a heightened sensitivity to mildly painful stimuli (hyperalgesia) or to normally innocuous stimuli (allodynia).
AK Inhibition of Pathological Pain
Inhibitors of AK have emerged as potent antinociceptive agents with a potentially improved therapeutic window over direct acting ADO receptor agonists. Systemic and local delivery of prototypic nucleoside (5'd-5IT, NH 2 dADO, and 5-IT) AK inhibitors have been effective in several animal models of nociception [35, [128] [129] [130] [131] , however, the therapeutic utility of these compounds is limited by their short half-lives in vivo, poor cell penetrability and bioavailability, lack of pharmacological selectivity, as well as their potential to form cytotoxic metabolites [30, 33, 132] . These limitations of the prototypical compounds have been overcome with the recent development of structurally novel nonnucleoside (ABT-702) and carbocyclic (A-134974, ABT-501) AK inhibitors [27, 31, 40, 43, 125] . These compounds share a similar profile to reduce nociception. In animals, systemic administration of these novel AK inhibitors alleviates acute nociception, neuropathic allodynia, chemogenic nociception, and inflammatory thermal hyperalgesia. Table 3 summarizes the antinociceptive profile of ABT-702, A-134974 and ABT-501. Each of these compounds has oral activity and was most effective in models of inflammatory hyperalgesia (carrageenan, complete Freund's adjuvant) with slightly improved efficacy over morphine [32, 125] . These AK inhibitors were also more potent to attenuate hyperalgesia than the accompanying paw edema [32, 40] , suggesting that pain relief was not secondary to a significant reduction of inflammation. The antihyperalgesic effects of ABT-702, A-134974 and ABT-501 were selective for the inflamed but not the noninflamed hindpaw, a result consistent with the proposed beneficial effects of increased ADO concentrations at sites of injury or trauma [10, 19] .
AK Inhibitor Improved Therapeutic Window
The antinociceptive actions of ABT-702, A-134974, and ABT-501 are also distinctly separable from side effects typically associated with direct acting ADO receptor agonists. A 10-to16-fold separation between ED 50 values for hypomotive and antihyperalgesic actions was observed for the novel AK inhibitors (Table 4) [36] . In contrast, there was considerably less separation between effects in these assays following administration of direct acting ADO receptor agonists with the largest ratio of effect being only 4.3 [36] . ADO and related receptor agonists are also potent modulators of cardiovascular activity. Acting at both central and peripheral sites, A 1 , A 2A , and A 2B receptor agonists can significantly depress arterial pressure and heart rate [133] [134] [135] . There is virtually no separation between cardiodepressant doses of NECA, CGS 21680 and CPA [136] [137] [138] in normotensive rats and the doses needed to elicit rat antihyperalgesia [36] . Conversely, ABT-702 and ABT-501 are reported to have minimal effects on heart rate and blood pressure [32, 40] . ABT-702 did not affect heart rate at doses up to 300 µmol/kg (p.o.), and only at this dose produced a slight reduction in mean arterial pressure (ED 50 in carrageenan hyperalgesia was 5 µmol/kg, p.o.). Furthermore, ABT-501 at doses up to 100 µmol/kg (p.o.) did not affect mean arterial pressure, and only at the 100 µmol/kg dose, had modest, transient and bi-directional, alterations in heart rate (ED 50 in carrageenan hyperalgesia was 1 µmol/kg, p.o.).
Site(s) of AK Inhibitor Antinociceptive Action
The antinociceptive actions of AK inhibition target primarily spinal sites of action [125, 126] . Antihyperalgesia following intracerebroventricular (ED 50 = 100 nmol) or intraplantar (ED 50 > 300 nmol) injection of A-134974 was relatively weak compared with the effect following intrathecal administration (ED 50 = 6 nmol) [125] . Furthermore, site-specific antagonism o.f the systemic effects of A-134974 was observed after theophylline administration into the spinal cord or inflamed hindpaw but not the brain. Spinal sites, but not the supraspinal or peripheral hindpaw sites, were also responsible for the anti-allodynic action of A-134974 [126] . Direct administration of this compound into the spinal lumbar enlargement potently relieved tactile allodynia (ED 50 = 10 nmol) in rats with ligated L5-L6 nerves. Supraspinal or intraplantar administrations were ineffective. Additionally, intrathecal administration of theophylline antagonized the anti-allodynic effects of systemic A-134974. Like A-134974, direct-acting ADO receptor agonists have also shown improved antinociceptive efficacy after injection into the spinal cord compared with delivery into the brain [139] . Additionally, in both carrageenan-inflamed and nerve-injured animals, systemic administration of ABT-702 reduced noxious evoked (thermal and mechanical) firing of spinal wide dynamic range neurons [140] , an effect that may have been primarily mediated by a direct spinal action of ABT-702.
Supraspinal mechanisms are more likely to contribute to the hypomotive actions of AK inhibitors. Administration of A-134974 via three different routes of injection (i.c.v., i.t., and i.p.) depressed locomotor activity and each of these effects was selectively antagonized by supraspinal administration of theophylline [125] . The mechanisms underlying the antinociceptive and the hypomotive actions of AK inhibitors are clearly distinct.
Studies with selective ADO receptor antagonists have revealed differential contributions for ADO receptor subtypes to neuropathic and inflammatory nociceptive states. The anti-allodynic effects of ABT-702 in neuropathic animals were attenuated by the selective A 1 receptor antagonist CPT but not by the A 2A receptor antagonist DMPX [32] . Since spinal sites are the key contributors to the anti-allodynic effects of AK inhibitors [126] , the A 1 receptor interaction most likely occurred at the spinal level. Indeed, ADO-related analgesia in the spinal cord is thought to be mediated primarily by the A 1 receptor [131, [141] [142] [143] . In contrast, in the carrageenan model of inflammatory thermal hyperalgesia, both A 1 and A 2A receptor subtypes contributed to the antinociceptive action of systemically administered ABT-702 and NH 2 dADO [32, 144] . The A 1 receptor component of this response was most likely mediated by spinal sites [128, 131] . Although an antinociceptive role for central A 2A receptors cannot be totally ruled out, the contribution from this receptor was most likely peripheral [128, 145, 146] .
CONCLUSIONS
The recent development of structurally novel AK inhibitors has emerged as one approach to exploit the beneficial effects of enhancing endogenous ADO concentrations at sites of tissue trauma. The effectiveness of prototypical AK inhibitors in animal models of seizure and pain has spurned medicinal chemistry efforts to yield a variety of novel, potent and selective AK inhibitors based on both the purine nucleoside and nonnucleoside pharmacophores. Preclinical studies with these novel AK inhibitors have revealed potent analgesic and anti-seizure action while minimizing the undesirable side effects typically associated with systemic administration of direct acting ADO receptor agonists. While this review has focused on the therapeutic utility of novel AK inhibitors against pain and epileptic seizures, these agents may also prove useful against other pathological conditions such as inflammation and cerebral ischemia. The nucleoside AK inhibitor, GP-3269, is the only known compound of this class to have been studied in man (phase I), but data from these studies has not been disclosed. Furthermore, the clinical development of GP-3966, another nucleoside AK inhibitor with antinociceptive activity, was halted due to a preliminary report of central nervous system hemorrhage in rats and dogs [121] . Although the preclinical data has shown considerable promise, the therapeutic utility of AK inhibitors for clinical practice remains to be established.
